GAIL, NTPC, TVS Motor: Stocks to track on Monday
Stocks to watch on Monday, July 1: At around 8:13 am, GIFT Nifty futures traded lower by 0.08 per cent or 19.25 points at 24,113, indicating a muted to negative opening on the D-Street.Market benchmarks Sensex and Nifty halted their three-day record-hitting rally to close with losses on Friday as investors booked profit in banking, finance, and tech stocks despite a positive trend in global equities. Snapping a four-session winning run, equity indices succumbed to selling pressure after mid-session when profit-taking emerged on select counters. After hitting a fresh all-time high level in early trade, the 30-share index declined 210.45 points or 0.27 per cent to settle at 79,032.73. The Nifty went lower by 33.90 points or 0.14 per cent to 24,010.60. Here are some stocks that will be in focus on Monday, July 1:
(With inputs from agencies.)
Zydus Life/ Dr Reddy's Labs
Auto stocks
TVS Motor
Samvardhana Motherson International
Samvardhana Motherson International:
The company will sell its entire stake in Lauak CIM Aerospace Private Limited (LCA), a joint venture with Lauak International. LCA is a joint venture between CIM and Lauak. CIM tools hold 49.99 per cent, while Samvardhana Motherson International holds 55 per cent of CIM.
Bank of Baroda
GAIL
NTPC
Vodafone Idea:
Cochin Shipyard:
Cochin Shipyard:
The company's subsidiary Udupi Cochin Shipyard Limited (UCSL has entered into contract with Wilson ASA, Norway, for the design and construction of 4 TDW Dry Cargo vessels. The agreement has also been entered into for additional 4 vessels of the same type which will be formally contracted withinSeptember 19, 2024. The overall project of 8 vessels is worth around 1,100 crores and is to be executed within September 2028.
Orchid Pharma/ Cipla:
Orchid Pharma/ Cipla:
Orchid Pharma Limited, the only Indian pharma company to have ever invented a New Chemical Entity (NCE), today announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections(cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)indications. So, to ensure widespread distribution of this breakthrough antibiotic, the company has partnered with Cipla.